Genetic testing isn't pharmacogenomic (predicting drug metabolism) but rather peptide-pathway focused, revealing whether your appetite-regulating biology naturally favors GLP-1 response, dual-pathway therapy, or alternative approaches
What many people notice first is a change in their appetite
Figure 1 provides the study design schema
Spokespeople for Willow and Midi said clinicians use their judgment to prescribe the drugs to people they think would benefit medically from the shots
Results Primary Cohort After applying the inclusion and exclusion criteria, we identified 413 patients in the main cohort who achieved HbA1c 300 mg/g decreased from 6.5% at baseline to 4.1% in the 1st year and 5.5% in the 2nd year (shown in Supplementary Fig
Additionally, there is a potential risk of thyroid tumors, including medullary thyroid carcinoma